Avid Bioservices Inc (CDMO)

[EYEBUYSTOX]

PPHM on Updated 2013 Biotech Watchlist with an objective background:

http://jutiagroup.com/20130502-biotech-watchlist-2013-update-exciting-ideas-have-explosive-potential/

"It was also all the company needed to proceed to phase 3, since the small trial was not powered to show a statistically significant improvement in mOS.

Now Peregrine can map out its end-of-phase 2 meeting with the FDA, which should occur by midyear, and emerge from the meeting with a pivotal phase 3 trial designed in consultation that will, hopefully, begin by year-end. Meanwhile, in Q2/13, Zavoico expects the company to announce mOS results from its phase 2b study of bavituximab as a first-line therapy in NSCLC (in combination with carboplatin + paclitaxel), as well as phase 1 results from a pair of investigator-sponsored trials of bavituximab in HER2-negative breast cancer (with paclitaxel) and liver cancer (with sorafenib).